f8877925-49e4-420e-8bd8-cac3a47b67d1
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.400
- UV_RESPONSE_DN+0.400
- ANGIOGENESIS+0.300
- PROTEIN_SECRETION+0.300
- ANDROGEN_RESPONSE+0.200
- HEME_METABOLISM+0.200
- KRAS_SIGNALING_UP+0.200
- ALLOGRAFT_REJECTION+0.100
- APICAL_JUNCTION+0.100
- BILE_ACID_METABOLISM+0.100
Top 10 suppressed
- E2F_TARGETS-0.400
- MYC_TARGETS_V2-0.400
- CHOLESTEROL_HOMEOSTASIS-0.300
- DNA_REPAIR-0.300
- G2M_CHECKPOINT-0.300
- MTORC1_SIGNALING-0.300
- GLYCOLYSIS-0.200
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.200
- TNFA_SIGNALING_VIA_NFKB-0.200
- UNFOLDED_PROTEIN_RESPONSE-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A0HP-01A-12R-A084-07 | — | A | 0.814 |
| 2 | SRR8943000 | — | — | 0.805 |
| 3 | 8ee55a63-4e87-4c00-8012-4c87efdcb7ed | — | — | 0.795 |
| 4 | TCGA-50-5944-01A-11R-1755-07 | — | cohortA1 | 0.781 |
| 5 | TCGA-CR-7389-01A-11R-2016-07 | — | — | 0.769 |
| 6 | TCGA-G2-A2EC-01A-11R-A180-07 | — | — | 0.760 |
| 7 | TCGA-AR-A24T-01A-11R-A169-07 | — | A | 0.758 |
| 8 | TCGA-97-8174-01A-11R-2287-07 | — | cohortA2 | 0.753 |
| 9 | TCGA-D6-6824-01A-11R-1915-07 | — | — | 0.752 |
| 10 | TCGA-86-7714-01A-12R-2170-07 | — | cohortA1 | 0.738 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.400 | Cobimetinib | — uncovered |
| UV_RESPONSE_DN | 0.400 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.200 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.100 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.100 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.100 | Inavolisib | — uncovered |